Searching across hundreds of databases
Amyotrophic lateral sclerosis (ALS) is a devastating, fatal neurological disease that primarily affects spinal cord anterior horn cells and their axons for which there is no treatment. Here we report the use of a recombinant natural human IgM that binds to the surface of neurons and supports neurite extension, rHIgM12, as a therapeutic strategy in murine models of human ALS. A single 200 µg intraperitoneal dose of rHIgM12 increases survival in two independent genetic-based mutant SOD1 mouse strains (SOD1G86R and SOD1G93A) by 8 and 10 days, delays the onset of neurological deficits by 16 days, delays the onset of weight loss by 5 days, and preserves spinal cord axons and anterior horn neurons. Immuno-overlay of thin layer chromatography and surface plasmon resonance show that rHIgM12 binds with high affinity to the complex gangliosides GD1a and GT1b. Addition of rHIgM12 to neurons in culture increases α-tubulin tyrosination levels, suggesting an alteration of microtubule dynamics. We previously reported that a single peripheral dose of rHIgM12 preserved neurological function in a murine model of demyelination with axon loss. Because rHIgM12 improves three different models of neurological disease, we propose that the IgM might act late in the cascade of neuronal stress and/or death by a broad mechanism.
Pubmed ID: 26035393 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Prize4Life is a 501(c)(3) nonprofit organization dedicated to accelerating the discovery of treatments and cures for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig''s disease). Our mission is to accelerate the discovery of a treatment and a cure for ALS by using powerful incentives to attract new people and new ideas and to leverage existing efforts and expertise in the ALS field. Our Values: * Patients first. Avichai Kremer, one of the Harvard Business School students who founded Prize4Life, was diagnosed with ALS in 2004. We therefore know the disease firsthand and have a sense of urgency to find a treatment. We value patients and their viewpoints. Patients, please tell us what you think. * Global awareness. We plan to push ALS to the forefront of fatal disease issues. We need your help in order to do this. Get involved. * New people and new ideas. We believe important breakthroughs in ALS may reside in the minds and laboratories of people who are not currently researching the disease. Our platform is a bridge for reaching these people. Enter the competition. * Results. Research is traditionally funded upfront, before an idea is even tested. Our prize model ensures that only clear research results, vetted by a team of scientific advisors, are rewarded. grants; funding resource;.
View all literature mentionsMus musculus with name FVB-Tg(Sod1*G86R)M1Jwg/J from IMSR.
View all literature mentionsMus musculus with name FVB-Tg(Sod1*G86R)M1Jwg/J from IMSR.
View all literature mentionsMus musculus with name B6SJL-Tg(SOD1*G93A)1Gur/J from IMSR.
View all literature mentionsMus musculus with name NTac:SD-Tg(SOD1G93A)L26H from IMSR.
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
